Background: The advent of Remicade (R) biosimilars, Remsima (R), Inflectra (R) and, more recently, Flixabi (R), has brought along the potential to decrease the costs associated with this therapy, therefore increasing its access to a larger group of patients. However, and in order to assure a soft transition, one must make sure the assays and algorithms previously developed and optimized for Remicade perform equ...